Post on 14-Jul-2015
EORTC als Beispiel für Vernetzung und Zusammenarbeit in der Krebsforschung
Prof. Dr. med. Roger Stupp
European Organisation for Research and Treatment of
Cancer (EORTC), Brussels, Belgium &
Klinik für Oncology & Tumorzentrum
UniversitätsSpital Zürich
Dt: Die Europäische Organisation für Forschung und Therapie von Krebskrankheiten fr: L’organisation européenne de recherche et traitement du cancer
EORTC: The European Organisation for Research and Treatment of Cancer
2
Source: EORTC Annual Report 2012 -2013
EORTC aims to develop, conduct, coordinate,
and stimulate Pan-European translational and
clinical research to improve the standard of
cancer treatment for patients, and ultimately
increase survival and quality of life.
“”
Collaborations across many stakeholders
3
Yesterday Tomorrow
EORTC
Pharma &
Biotech
AcademiaCharitable
FundsEORTC
Pharma &
Biotech
Charitable
FundsAcademia
Gov’t
Bodies
Payers &
Health
Insurers
Patients
Technology
Companies
Regulators
& HTAs
?
?
Einige Tatsachen
• Krebs-Häufigkeit
• Krebs-Sterblichkeit
• Aus 10.000 chemischenSubstanzen entstehtlediglich ein Arzneimittel
Forschung
5
Drug DevelopmentPosition of EORTC
6
EORTC
• Private and not for profit organization created in 1962
• Main mission: promote and conduct researchto improve cancer care
• Core activity: conduct clinical trials
International
Multidisciplinary
Develop new treatments
Define new standards of care
Large academic trials
EUROPEAN ORGANIZATION FOR RESEARCH
AND TREATMENT OF CANCER (EORTC)
Henri Tagnon, Co-founder of EORTC
EORTC TODAY (2014)
• Network of more than 300 institutions from 29 different countries
• +/- 2,000 collaborators (clinicians, pathologists, researchers,....)
• About 6,000 patients are entered into EORTC trials each year (database of more than 150,000 patients)
• 50,000 patients being followed-up
• +/-30 trials open to patient entry
ACCRUAL OF PATIENTS IN EORTC STUDIES
(2000 – 2011) 71.905 PATIENTS
European Union: Austria: 810Belgium: 7.399Bulgaria: 49Cyprus: 73Czech Republic: 160Denmark: 529Estonia: 7Finland: 34France: 14.438Germany: 6.310Greece: 48Hungary: 210Italy: 6.553Latvia: 34Luxemburg: 9Malta: 20Poland: 1.082Portugal: 635Republic of Ireland: 90Romania: 20
Non-EU CountriesBosnia: 8Croatia: 352Macedonia: 6Norway: 454Serbia : 261Russia: 178Switzerland: 1.438Turkey: 631Ukraine: 4
Rest of the World: 3.941 patients
European Union (con’t):Slovak Republic: 451Slovenia: 310Spain: 2.867Sweden: 595The Netherlands: 15.279United Kingdom: 6.620
9
GIST: a very rare diseaseIncidence: 10-15/Mio CH: ca 75 neue Pat/Jahr
N Engl J Med 2001; 344:1052-1056
Eur J Cancer 2003, 39:2006-11
Lancet 2004; 364:1127-1134
EORTC 62024 (PI: P. Casalli)
EORTC 62024
EORTC 62062: GIST- Sx ± adj imatinib
(years)
0 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : Treatment arm
160 453 344 309 278 207 95 28
121 454 429 410 359 250 105 21
Observation
Imatinib adjuvant
Relapse free survival
(years)
0 1 2 3 4 5 6 7
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : Treatment arm
29 454 435 425 407 310 143 35
33 454 444 435 413 322 153 31
Observation
Imatinib adjuvant
Overall Survival
Relapse-free survival Overall survival
Treatment arm% at 5 Year(s)
(98.5% CI)
Observation99.10
(96.99, 99.73)
Imatinib Adj.99.78
(97.49, 99.98)
Treatment arm% at 3 Year(s)
(98.5% CI)
% at 5 Year(s)
(98.5% CI)
Observation65.83
(60.00, 71.03)
62.99
(56.93, 68.44)
Imatinib Adj.84.26
(79.48, 88.01)
69.40
(62.97, 74.94)
HR (adjusted for R0 vs R1, tumor site and risk group) : HR=0.58 (98.5%CI: 0.43-0.78)P<0.0001
Casalli et al. Proc ASCO 2013
EORTC: Numerous publicatations
Personalized MedicineFrequent Tumors become Rare
Harris et al. Discov Med 10(51):144-150, August 2010
Lung cancer is not
what it used to be
Adenocarcinoma
Pao, Nature Med 2012
Small cell lung cancer
Non-small cell lung cancer
CrizotinibXalkori®
VemurafenibZelboraf®
TrastuzumabHerceptin®
Gefitinib/ErlotinibIressa®/Tarceva®
CetuximabErbitux®
“Druggable” molecular abberations
Research Requires Infrastructure
• Preclinical • Clinical
! "#$%! "#$%&'(") %#*%#*+, *
! "&' %-. /& '#"01*
! ""' %*2"-"3"1. *%#*4 '#$%5 1*
( ) ) ) %4 . 3*60'#'6"0*"770'6") %#1*
( ) ! ( %*, 0%8$*6%&78) #9*
! ""**: ; ! <, *%#*-=. *5 . 3*
! "&) *78#6=*6"/$1*
Collaborations across many stakeholders
20
Yesterday Tomorrow
EORTC
Pharma &
Biotech
AcademiaCharitable
FundsEORTC
Pharma &
Biotech
Charitable
FundsAcademia
Gov’t
Bodies
Payers &
Health
Insurers
Patients
Technology
Companies
Regulators
& HTAs
?
?
The future of cancer therapy
EORTC PRESIDENTS 1962-2015
towards the future…
23